Raloxifene reduces circulating levels of interleukin-7 and monocyte chemoattractant protein-1 in postmenopausal women

被引:15
|
作者
Yasui, Toshiyuki [1 ]
Uemura, Hirokazu [2 ]
Hyodo, Sari [3 ]
Yamada, Masayo [1 ]
Yamamoto, Satoshi [1 ]
Maegawa, Masahiko [1 ]
Tsuchiya, Naoko
Noguchi, Masamichi
Yuzurihara, Mitsutoshi
Kase, Yoshio
Irahara, Minoru [1 ]
机构
[1] Univ Tokushima, Dept Obstet & Gynecol, Course Human Dev Human Dev & Hlth Sci, Inst Hlth Biosci,Grad Sch, Tokushima 7708503, Japan
[2] Univ Tokushima, Dept Prevent Med, Course Human Dev Human Dev & Hlth Sci, Inst Hlth Biosci,Grad Sch, Tokushima 7708503, Japan
[3] Univ Tokushima, Course Med, Sch Med, Tokushima 7708503, Japan
关键词
Raloxifene; Interleukin-7; MCP-1; TUMOR-NECROSIS-FACTOR; ENDOTHELIUM-DEPENDENT VASODILATION; RECEPTOR MODULATOR RALOXIFENE; SERUM CYTOKINE CONCENTRATIONS; INSULIN-RESISTANCE; ADIPOSE-TISSUE; CARDIOVASCULAR EVENTS; CHEMOTACTIC PROTEIN-1; HUMAN OBESITY; FACTOR-ALPHA;
D O I
10.1016/j.atherosclerosis.2008.09.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The aim of the present study was to determine the effects of raloxifene on changes in circulating levels of cytokines and chemokines in relation to changes in lipid profiles and markers of inflammation in postmenopausal women. Methods: Fifty-three postmenopausal women aged 45-65 years old were randomly assigned in open, parallel-group fashion to a control group or raloxifene group. Twenty-six women received oral administration of 60 mg raloxifene every day and 27 women did not receive any drugs for 12 months. Serum cytokines levels were simultaneously measured using a multiplexed human cytokine assay. Results: Serum IL-7 concentrations in women who received raloxifene were decreased significantly (p = 0.014), and serum monocyte chemoattractant protein (MCP)-1 concentrations in women who received raloxifene were decreased significantly (p=0.0003) at 12 months. In the control group, serum levels of MCP-1 and IL-7 did not show significant changes. There were significant differences (p = 0.032 and p = 0.0024, respectively) in percentage changes in IL-7 and MCP-1 in the control group and in the raloxifene group. Levels of low-density lipoprotein cholesterol (LDL-C) and E-selectin were decreased significantly in women who received raloxifene, but the percentage changes in LDL-C and E-selectin over a period of 12 months were not significantly correlated with percentage changes in IL-7 and MCP-1 over the same period. Conclusion: Circulating levels of IL-7 and MCP-1 decrease in postmenopausal women who received raloxifene. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:471 / 475
页数:5
相关论文
共 50 条
  • [21] Monocyte chemoattractant protein-1 levels in patients with glomerular disease
    Rovin, BH
    Doe, N
    Tan, LC
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 27 (05) : 640 - 646
  • [22] Monocyte chemoattractant protein-1 and the kidney
    Haller, Hermann
    Bertram, Anna
    Nadrowitz, Felix
    Menne, Jan
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2016, 25 (01): : 42 - 49
  • [23] Relationship between circulating levels of monocyte chemoattractant protein-1 and systolic dysfunction in patients with hypertrophic cardiomyopathy
    Iwasaki, Jun
    Nakamura, Kazufumi
    Matsubara, Hiromi
    Nakamura, Yoichi
    Nishii, Nobuhiro
    Banba, Kimikazu
    Murakami, Masato
    Ohta-Ogo, Keiko
    Kimura, Hideo
    Toh, Norihisa
    Nagase, Satoshi
    Oka, Takefumi
    Morita, Hiroshi
    Kusano, Kengo Fukushima
    Ohe, Tohru
    CARDIOVASCULAR PATHOLOGY, 2009, 18 (06) : 317 - 322
  • [24] Circulating levels of monocyte chemoattractant protein-1 as a potential measure of biological age in mice and frailty in humans
    Yousefzadeh, Matthew J.
    Schafer, Marissa J.
    Noren Hooten, Nicole
    Atkinson, Elizabeth J.
    Evans, Michele K.
    Baker, Darren J.
    Quarles, Ellen K.
    Robbins, Paul D.
    Ladiges, Warren C.
    LeBrasseur, Nathan K.
    Niedernhofer, Laura J.
    AGING CELL, 2018, 17 (02)
  • [25] Simultaneous elevation of the levels of circulating monocyte chemoattractant protein-1 and tissue factor in acute coronary syndromes
    Nishiyama, K
    Ogawa, H
    Yasue, H
    Soejima, H
    Misumi, K
    Takazoe, K
    Yoshimura, M
    Kugiyama, K
    Tsuji, I
    Kumeda, K
    JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 1998, 62 (09): : 710 - 712
  • [26] Involvement of monocyte chemoattractant protein-1, macrophage inflammatory protein-1α and interleukin-1β in Wallerian degeneration
    Perrin, FE
    Lacroix, S
    Avilés-Trigueros, M
    David, S
    BRAIN, 2005, 128 : 854 - 866
  • [27] Association of circulating monocyte chemoattractant protein-1 levels with polycystic ovary syndrome: A meta-analysis
    Wu, Ze
    Fang, Lanlan
    Li, Yuxi
    Yan, Yang
    Thakur, Avinash
    Cheng, Jung-Chien
    Sun, Ying-Pu
    AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2021, 86 (02)
  • [28] CIRCULATING MONOCYTE CHEMOATTRACTANT PROTEIN-1 LEVELS ARE ELEVATED AND CORRELATED WITH ENDOTHELIN-1 IN PATIENTS WITH SYSTEMIC SCLEROSIS
    Park, S. H.
    Kwok, S. K.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (02) : S173 - S173
  • [29] The levels of circulating and urinary monocyte chemoattractant protein-1 are associated with chronic renal injury in obese men
    Fu, Chia-Po
    Lee, I-Te
    Sheu, Wayne H. -H.
    Lee, Wen-Jane
    Liang, Kae-Woei
    Lee, Wen-Lieng
    Lin, Shih-Yi
    CLINICA CHIMICA ACTA, 2012, 413 (19-20) : 1647 - 1651
  • [30] Monocyte Chemoattractant Protein-1 and Interleukin-8 Levels in Acute Inflammation Induced by Prolonged Exercise
    Skenderi, Katerina P.
    Papassotiriou, Ioannis
    Mitrakou, Asimina
    Mastorakos, George
    Anastasiou, Costas A.
    Tsironi, Maria
    FASEB JOURNAL, 2010, 24